Weakened role for Brazilian medicines agency in granting patents is not enough, says industry
This article was originally published in SRA
Brazil's R&D-based industry association, Interfarma, has welcomed a controversial legal decision to restrict the powers of medicines regulator Anvisa in the granting of patents. Nevertheless, it says the move does not go far enough. Meanwhile, civil society groups claim the decision is a setback for public health and are taking their case to the United Nations.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.